^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MP0274

    i
    Other names: MP0274, MP 0274, MP-0274
    Company:
    Molecular Partners
    Drug class:
    HER2 inhibitor
    Related drugs:
    almost4years
    First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors (clinicaltrials.gov)
    P1, N=22, Completed, Molecular Partners AG | Active, not recruiting --> Completed | N=46 --> 22
    Clinical • Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    MP0274
    4years
    First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Molecular Partners AG | Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    MP0274
    almost6years
    First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors (clinicaltrials.gov)
    P1, N=46, Recruiting, Molecular Partners AG | Trial completion date: Feb 2020 --> Sep 2021 | Trial primary completion date: Nov 2019 --> Jun 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    MP0274